• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: STAAR SURGICAL COMPANY ICL (IMPLANTABLE COLLAMER LENS); INTRAOCULAR LENS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

STAAR SURGICAL COMPANY ICL (IMPLANTABLE COLLAMER LENS); INTRAOCULAR LENS Back to Search Results
Model Number MICL13.2
Device Problems Inadequacy of Device Shape and/or Size (1583); Appropriate Term/Code Not Available (3191)
Patient Problems Cataract, Induced (1767); Loss of Vision (2139); No Code Available (3191)
Event Date 07/21/2014
Event Type  Injury  
Manufacturer Narrative
(b)(4).Lens not returned.
 
Event Description
The patient reported the surgeon implanted a 13.2mm micl13.2 implantable collamer lens, -8.0 diopter, in her left eye (os).The patient reported she had lost vision due to the development of a cataract (anterior subcapsular).The lens had a low vault.The lens was explanted on (b)(6) 2015, the cataract was removed and an iol was implanted.The patient's post-op va was 20/20.
 
Manufacturer Narrative
Method: medical review, work order search.Results: per medical review: reportedly icl was explanted 3 years postoperatively to address low vault and a cataract development.According to completed data clarification request, dated on (b)(6) 2015, the type of cataract was anterior subcapsular and was attributed to the device.Following icl removal, cataract was extracted, and iol was successfully implanted.The same report stated that the patient prognosis was good (va:20/20).It should be noted that at the time of the icl implantation patient was (b)(6) and per dfu indications: "the visian icl is indicated for use in adults 21-45 years of age" therefore, there is no sufficient safety and effectiveness data to support implantation in such patients and that was reflected in device causality.Furthermore, literature reports that only 1-2% of patients develop clinically significant cataract following icl implantation probably due to patient related factors (especially high myopes and older patients).A work order search found no similiar complaints.Conclusion: based on the complaint history, work order search, and medical review, a specific root cause of the event could not be determined.(b)(4).
 
Manufacturer Narrative
(b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ICL (IMPLANTABLE COLLAMER LENS)
Type of Device
INTRAOCULAR LENS
Manufacturer (Section D)
STAAR SURGICAL COMPANY
haupstrasse 104
nidau, CH-25 60
SZ  CH-2560
Manufacturer (Section G)
STAAR SURGICAL COMPANY
haupstrasse 104
nidau, CH-25 60
SZ   CH-2560
Manufacturer Contact
althea watson
1911 walker avenue
monrovia, CA 91016
6263037902
MDR Report Key5327964
MDR Text Key34378206
Report Number2023826-2015-01752
Device Sequence Number1
Product Code MTA
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P030016
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer,study
Reporter Occupation Patient
Type of Report Initial,Followup,Followup
Report Date 05/26/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Physician
Device Expiration Date12/31/2013
Device Model NumberMICL13.2
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Initial Date Manufacturer Received 05/26/2015
Initial Date FDA Received12/24/2015
Supplement Dates Manufacturer ReceivedNot provided
Not provided
Supplement Dates FDA Received03/16/2016
09/16/2016
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured01/30/2012
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age57 YR
-
-